Denali Therapeutics Inc. (DNLI) PT Raised to $53 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts DNLI Hot Sheet
Price: $18.86 --0%
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Join SI Premium – FREE
Wedbush analyst Laura Chico raised the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $53.00 (from $50.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Citi Downgrades Ser Educacional SA (SEER3:BZ) to Neutral
- Pizza Pizza Royalty Corp. (PZA:CN) (PZRIF) PT Lowered to Cdn$11 at TD Securities
- Huntington Ingalls (HII) PT Raised to $375 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
